Mendonça-de-Pontes, RoberiaFlores-Montero, JuanSanoja-Flores, LuzalbaPuig, NoemiPessoa-de-Magalhães, Roberto JCorral-Mateos, AlbaSalgado, Anna BeatrizGarcia-Sanchez, OmarPerez-Moran, JoseMateos, Maria-VictoriaBurgos, LeirePaiva, BrunoTe-Marvelde, Jeroenvan-der-Velden, Vincent H JAguilar, CarlosBarez, AbelardoGarcia-Mateo, AranzazuLabrador, JorgeLeoz, PilarAguilera-Sanz, CarmenDurie, Brianvan-Dongen, Jacques J MMaiolino, AngeloSobral-da-Costa, ElaineOrfao, Alberto2023-02-092023-02-092021-04-03Mendonça de Pontes R, Flores-Montero J, Sanoja-Flores L, Puig N, Pessoa de Magalhães RJ, Corral-Mateos A, et al. B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients. Cancers (Basel). 2021 Apr 3;13(7):1704.2072-6694http://hdl.handle.net/10668/17662B-cell regeneration during therapy has been considered as a strong prognostic factor in multiple myeloma (MM). However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated during follow-up. MM (n = 177) and adult (≥50y) healthy donor (HD; n = 14) BM samples were studied by next-generation flow (NGF) to simultaneously assess measurable residual disease (MRD) and residual normal B-cell populations. BM hemodilution was detected in 41 out of 177 (23%) patient samples, leading to lower total B-cell, B-cell precursor (BCP) and normal plasma cell (nPC) counts. Among MM BM, decreased percentages (vs. HD) of BCP, transitional/naïve B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP increased after induction therapy, whereas TBC/NBC counts remained abnormally low. At day+100 postautologous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC cell numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19- nPC counts vs. non-CR specimens. MRD positivity was associated with higher BCP and nPC percentages. Hemodilution showed a negative impact on BM B-cell distribution. Different BM B-cell regeneration profiles are present in MM at diagnosis and after therapy with no significant association with patient outcome.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/B-cell regenerationhemodilutionimmunophenotypingmeasurable residual diseasemultiple myelomaAdultBone MarrowFollow-Up StudiesHemodilutionInduction ChemotherapyMultiple MyelomaPlasma CellsPrognosisStem Cell TransplantationCell Countresearch article33916787open accessTerapéuticaCélulasHemodiluciónRegeneraciónDiagnósticoRecuento de célulasTrasplante de células madreDonantes de tejidosCélulas plasmáticasMieloma múltiple10.3390/cancers13071704PMC8038337https://www.mdpi.com/2072-6694/13/7/1704/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038337/pdf